Arca
Skip to content
Tools
Tools

GRM2: Metabotropic glutamate receptor 2

Dimeric G protein-coupled receptor which is activated by the excitatory neurotransmitter L-glutamate.

  • Drugs that act on it: 6
  • Approved: 0
  • In phases 1 to 3: 6
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on GRM2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 5
  • Other 1

Approved0

    Phase 31

    Phase 22

    • Decoglurant
    • JNJ-40411813

    Phase 13

    • LY2969822
    • LY2979165
    • LY404039

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Denovo Biopharma LLC117%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 4 of 6 act as: Metabotropic glutamate receptor 2 agonist; the rest name their own mechanism.
    Pomaglumetad methionil anhydrousPhase 3Denovo Biopharma LLCSmall moleculeAgonist0
    DecoglurantPhase 2RocheSmall moleculeModulatorMetabotropic glutamate receptor 2 modulator0
    JNJ-40411813Phase 2Johnson & JohnsonSmall moleculePositive allosteric modulatorMetabotropic glutamate receptor 2 positive allosteric modulator0
    LY2969822Phase 1—OtherAgonist0
    LY2979165Phase 1Eli LillySmall moleculeAgonist0
    LY404039Phase 1—Small moleculeAgonist0

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Neurodegenerative disease0.27
    • Crystal arthropathy0.20
    • Abnormality of the skeletal system0.19
    • Psychiatric disorder0.08
    • Seizure0.07
    • Parkinson disease0.07
    • Genetic developmental and epileptic encephalopathy0.07

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5137, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q14416, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.